Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 19

1.

JAK2 V617F mutation, mesenteric vein thrombosis, and myeloproliferative disorders.

Owens CD.

J Vasc Surg. 2010 Jul;52(1):205-7. doi: 10.1016/j.jvs.2010.01.097.

2.

JAK2 V617F: implications for thrombosis in myeloproliferative diseases.

Hexner EO.

Curr Opin Hematol. 2007 Sep;14(5):450-4. Review.

PMID:
17934351
3.

JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature.

Michiels JJ, Commandeur S, Hoogenboom GJ, Wegman JJ, Scholten L, van Rijssel RH, De Raeve H.

Ann Hematol. 2007 Nov;86(11):793-800. Review.

PMID:
17687555
4.

JAK2V617F mutation in patients with thrombosis: to screen or not to screen?

Xavier SG, Gadelha T, Rezende SM, Zalcberg IR, Spector N.

Int J Lab Hematol. 2011 Apr;33(2):117-24. doi: 10.1111/j.1751-553X.2010.01275.x. Review.

PMID:
21118380
5.

The JAK2 V617F mutation and thrombosis.

Austin SK, Lambert JR.

Br J Haematol. 2008 Nov;143(3):307-20. Review. Erratum in: Br J Haematol. 2008 Nov;143(3):451.

PMID:
19004076
6.

Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).

Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.

Pathol Biol (Paris). 2007 Mar;55(2):92-104. Review.

PMID:
16919893
7.

Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders.

Marchetti M, Falanga A.

Pathophysiol Haemost Thromb. 2008;36(3-4):148-59. doi: 10.1159/000175153. Review.

PMID:
19176988
8.
9.

Essential thrombocythemia: scientific advances and current practice.

Tefferi A.

Curr Opin Hematol. 2006 Mar;13(2):93-8. Review.

PMID:
16456375
10.
13.

JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.

Oh ST, Gotlib J.

Expert Rev Hematol. 2010 Jun;3(3):323-37. doi: 10.1586/ehm.10.28. Review.

PMID:
21082983
14.

[Myeloproliferative diseases caused by JAK2 mutation].

Nagata K, Shimoda K.

Rinsho Byori. 2009 Apr;57(4):357-64. Review. Japanese.

PMID:
19489438
15.

Prothrombotic disorders in abdominal vein thrombosis.

Leebeek FW, Smalberg JH, Janssen HL.

Neth J Med. 2012 Nov;70(9):400-5. Review.

16.

Standard anticoagulation for mesenteric vein thrombosis, revealing a 'zebra' diagnosis: hereditary haemorrhagic telangiectasia--the dripping truth!

Aggarwal A, Kahlon AS, Rane M, Banas E.

BMJ Case Rep. 2013 Oct 28;2013. pii: bcr2013200045. doi: 10.1136/bcr-2013-200045. Review.

17.

Clinical approach to splanchnic vein thrombosis: risk factors and treatment.

Riva N, Donadini MP, Dentali F, Squizzato A, Ageno W.

Thromb Res. 2012 Oct;130 Suppl 1:S1-3. doi: 10.1016/j.thromres.2012.08.259. Review.

PMID:
23026649
18.

Mesenteric vein thrombosis after laproscopic gastric sleeve procedure.

Gandhi K, Singh P, Sharma M, Desai H, Nelson J, Kaul A.

J Thromb Thrombolysis. 2010 Aug;30(2):179-83. doi: 10.1007/s11239-009-0434-z. Review. No abstract available.

PMID:
20140480
19.

Splanchnic vein thrombosis in myeloproliferative neoplasms.

Sekhar M, McVinnie K, Burroughs AK.

Br J Haematol. 2013 Sep;162(6):730-47. doi: 10.1111/bjh.12461. Review.

PMID:
23855810
Items per page

Supplemental Content

Support Center